FDA clearance for Stelo expansion puts DexCom (DXCM) back in focus

DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use of its Stelo Glucose Biosensor for children aged 2 and older who do not use insulin, along with new international rollout plans.

After the FDA clearance, DexCom’s recent 1 day share price return of 2.17% contrasts with a softer 7 day share price return of 3.22% and a 30 day share price return of 4.88%. The 90 day share price return of 13.31% sits against a 1 year total shareholder return that declined 18.75% and a 3 year total shareholder return that declined 45.42%, suggesting short term momentum has picked up even as longer term holders remain under pressure.

If this kind of regulatory driven move has your attention, it could be a useful moment to broaden your research and check out 39 healthcare AI stocks

With DexCom trading at an intrinsic discount estimate of about 40%, and roughly 22% below the average analyst price target, are investors looking at a genuine value opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 15.9% Undervalued

Compared with DexCom’s last close at $70.14, the most followed valuation narrative points to a higher fair value, framing today’s price as a discount worth examining.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Want to see what sits behind that view? The narrative leans on steady revenue gains, firmer margins and a valuation multiple that assumes investors stay comfortable with long term earnings power.

Result: Fair Value of $83.42 (UNDERVALUED)

However, DexCom’s story still carries risks, particularly potential pricing pressure from proposed CMS competitive bidding and the threat of stronger competition in core CGM markets.

Another view on DexCom's valuation

While the narrative-led fair value suggests DexCom is undervalued, the current P/E of 29.1x tells a tighter story. It sits above the US Medical Equipment industry at 26.2x and also above peer average at 21.3x, yet is close to a fair ratio estimate of 29.5x. That narrow gap implies the share price may already reflect much of the current earnings profile, so the focus may now be more on future delivery rather than on today's discount.

For a closer look at how the current P/E compares with what the market could move toward, check the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of short term momentum, valuation debate and FDA news around DexCom leaves you curious, take a moment to test the numbers yourself and stress test the narrative before markets move on. To see which potential bright spots our model is flagging, review the 4 key rewards

Looking for more investment ideas beyond DexCom?

Do not stop your research with DexCom. Widen your watchlist now or you risk missing stocks that better match your goals, risk profile and time horizon.

• Target potential mispricing by scanning for companies trading below assessed worth using the 44 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with strong finances through the solid balance sheet and fundamentals stocks screener (48 results).
• Strengthen potential income streams by reviewing companies offering higher yields via the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.